Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Comparison of the Efficacy and Safety of the Low-Molecular-Weight Heparin [certoparin sodium] (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-Surgical Patients.

Trial Profile

An Open-Label Comparison of the Efficacy and Safety of the Low-Molecular-Weight Heparin [certoparin sodium] (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-Surgical Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certoparin sodium (Primary) ; Heparin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms CERTAIN
  • Sponsors Novartis

Most Recent Events

  • 01 Dec 2010 Results published in the Expert Opinion on Pharmacotherapy.
  • 11 Jul 2009 Results presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
  • 03 Nov 2008 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top